In vivo type 1 cannabinoid receptor availability in Alzheimer's disease

被引：50

作者：

Ahmad, Rawaha ^{[1
,2
]}

Goffin, Karolien ^{[1
,2
]}

Van den Stock, Jan ^{[3
,4
]}

De Winter, Francois-Laurent ^{[3
,4
]}

Cleeren, Evy ^{[1
,2
]}

Bormans, Guy ^{[5
]}

Tournoy, Jos ^{[1
,6
]}

Persoons, Philippe ^{[3
,4
]}

Van Laere, Koen ^{[1
,2
]}

Vandenbulcke, Mathieu ^{[3
,4
]}

机构：

[1] Katholieke Univ Leuven Hosp, B-3000 Louvain, Belgium

[2] Katholieke Univ Leuven, Dept Imaging & Pathol, Louvain, Belgium

[3] Katholieke Univ Leuven Hosp, Dept Old Age Psychiat, B-3000 Louvain, Belgium

[4] Katholieke Univ Leuven, Dept Neurosci, Louvain, Belgium

[5] Katholieke Univ Leuven, Lab Radiopharm, Louvain, Belgium

[6] Katholieke Univ Leuven, Dept Clin & Expt Med, Louvain, Belgium

来源：

EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2014年 / 24卷 / 02期

关键词：

Alzheimer's disease; Cannabinoid receptor; Amyloid; PET scan; MMSE; ApoE; HUNTINGTONS-DISEASE; AMYLOID-DEPOSITION; COGNITIVE IMPAIRMENT; BASAL GANGLIA; CB1; RECEPTORS; HUMAN BRAIN; PET TRACER; A-BETA; DEMENTIA; MEMORY;

D O I：

10.1016/j.euroneuro.2013.10.002

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The endocannabinoid system (ECS) is an important modulatory and potentially neuroprotective homeostatic system in the brain. In Alzheimer's disease (AD), the role of type 1 cannabinoid receptor (CB1R) is unclear, with contradictory findings in post-mortem studies showing upregulation, down-regulation or unchanged CB1R status. We have investigated CB1R availability in vivo in patients with AD, in relation to amyloid deposition, cognitive functioning and apolipoprotein E (ApoE) genotype. Eleven AD patients and 7 healthy volunteers (HV) underwent combined [F-18]MK-9470 PETand [C-11]PlB PET scans to assess CB1R availability and amyloid deposition, respectively, and T1 volumetric MRI for partial volume correction. We found no difference in CB1R availability between AD and HV, VOI-based fractional uptake values (FUR) were 0.043 +/- 0.01 for AD and 0.045 +/- 0.01 for controls (p=0.9). CB1R availability did not correlate with neuropsychological test scores and was not modulated by ApoE genotype. As expected, global [C-11]PlB SUVR (standardized uptake value ratio) was increased in AD (SUVR 1.9 +/- 0.3) compared to HV (1.2 +/- 0.1) with p < 0.001, but no correlation was found between amyloid beta (A beta) deposition and CB1R availability. In conclusion, we found no in vivo evidence for a difference in CB1R availability in AD compared to age-matched controls. Taken together with recently reported in vivo CB1R changes in Parkinson's and Huntington's disease, these data suggest that the CB1R is differentially involved in neurodegenerative disorders. (C) 2013 Elsevier B.V. and ECNP. All rights reserved.

引用

页码：242 / 250

页数：9

共 48 条

[1] Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly [J].

Aizenstein, Howard Jay ;

Nebes, Robert D. ;

Saxton, Judith A. ;

Price, Julie C. ;

Mathis, Chester A. ;

Tsopelas, Nicholas D. ;

Ziolko, Scott K. ;

James, Jeffrey A. ;

Snitz, Beth E. ;

Houck, Patricia R. ;

Bi, Wenzhu ;

Cohen, Ann D. ;

Lopresti, Brian J. ;

DeKosky, Steven T. ;

Halligan, Edythe M. ;

Klunk, William E. .

ARCHIVES OF NEUROLOGY, 2008, 65 (11) :1509-1517

[2]

Albinski R, 2011, PSYCHIATR POL, V45, P555

[3] CB1 Agonist ACEA Protects Neurons and Reduces the Cognitive Impairment of AβPP/PS1 Mice [J].

Aso, Ester ;

Palomer, Ernest ;

Juves, Salvador ;

Maldonado, Rafael ;

Munoz, Francisco J. ;

Ferrer, Isidro .

JOURNAL OF ALZHEIMERS DISEASE, 2012, 30 (02) :439-459

[4] Learning, retrieval, and recognition are compromised in aMCI and mild AD: Are distinct episodic memory processes mediated by the same anatomical structures? [J].

Balthazar, Marcio L. F. ;

Yasuda, Clarissa L. ;

Cendes, Fernando ;

Damasceno, Benito P. .

JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 2010, 16 (01) :205-209

[5]

Benito C, 2003, J NEUROSCI, V23, P11136

[6] [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor [J].

Burns, H. Donald ;

Van Laere, Koen ;

Sanabria-Bohorquez, Sandra ;

Hamill, Terence G. ;

Bormans, Guy ;

Eng, Wai-si ;

Gibson, Ray ;

Ryan, Christine ;

Connolly, Brett ;

Patel, Shil ;

Krause, Stephen ;

Vanko, Amy ;

Van Hecken, Anne ;

Dupont, Patrick ;

De Lepeleire, Inge ;

Rothenberg, Paul ;

Stoch, S. Aubrey ;

Cote, Josee ;

Hagmann, William K. ;

Jewell, James P. ;

Lin, Linus S. ;

Liu, Ping ;

Goulet, Mark T. ;

Gottesdiener, Keith ;

Wagner, John A. ;

de Hoon, Jan ;

Mortelmans, Luc ;

Fong, Tung M. ;

Hargreaves, Richard J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (23) :9800-9805

[7] GENE DOSE OF APOLIPOPROTEIN-E TYPE-4 ALLELE AND THE RISK OF ALZHEIMERS-DISEASE IN LATE-ONSET FAMILIES [J].

CORDER, EH ;

SAUNDERS, AM ;

STRITTMATTER, WJ ;

SCHMECHEL, DE ;

GASKELL, PC ;

SMALL, GW ;

ROSES, AD ;

HAINES, JL ;

PERICAKVANCE, MA .

SCIENCE, 1993, 261 (5123) :921-923

[8] The neuropsychiatric inventory: Assessing psychopathology in dementia patients [J].

Cummings, JL .

NEUROLOGY, 1997, 48 (05) :S10-S16

[9] Functions of cannabinoid receptors in the hippocampus [J].

Davies, SN ;

Pertwee, RG ;

Riedel, G .

NEUROPHARMACOLOGY, 2002, 42 (08) :993-1007

[10] Research criteria for the diagnosis of Alzheimer"s disease: revising the NINCDS-ADRDA criteria [J].

Dubois, Bruno ;

Feldman, Howard H. ;

Jacova, Claudia ;

Dekosky, Steven T. ;

Barberger-Gateau, Pascale ;

Cummings, Jeffrey ;

Delocourte, Andre ;

Galasko, Douglas ;

Gauthier, Serge ;

Jicha, Gregory ;

Meguro, Kenichi ;

O'Brien, John ;

Pasquier, Florence ;

Robert, Philippe ;

Rossor, Martin ;

Solloway, Steven ;

Stern, Yaakov ;

Visser, Pieter J. ;

Scheltens, Philip .

LANCET NEUROLOGY, 2007, 6 (08) :734-746

← 1 2 3 4 5 →